• CHF 18.6 Million Rights Offering of Kuros Biosciences

    On 23 October 2020, Kuros Biosciences, a life science company focusing on the development and marketing of orthobiologics, completed a capital increase by way of a rights offering to its shareholders. 50.2% of the shareholders of Kuros Biosciences exercised their subscription rights in the rights offering. The remaining 4,192,530 offered shares were placed in the…


    Read more: CHF 18.6 Million Rights Offering of Kuros Biosciences